News
Videos
Conferences
Events
Resources
Subscribe

|Videos|August 17, 2015

Obesity and Nutrition as Cancer Risk Factors

Episodes in this series

EP. 1 Obesity and Nutrition as Cancer Risk Factors

EP. 1 Obesity and Nutrition as Cancer Risk Factors

EP. 2 Navigating Supplements and Organic Foods

EP. 2 Navigating Supplements and Organic Foods

EP. 3 The Cooking Studio at JTCC

EP. 3 The Cooking Studio at JTCC

EP. 4 Appetite Stimulants and Nutritional Markers

EP. 4 Appetite Stimulants and Nutritional Markers

EP. 5 Cancer: Top Nutritional Tips

EP. 5 Cancer: Top Nutritional Tips

EP. 6 Specific Nutritional Tips for Individual Cancers

EP. 6 Specific Nutritional Tips for Individual Cancers

EP. 7 Antioxidant-rich Recipes for Cancer Patients

EP. 7 Antioxidant-rich Recipes for Cancer Patients

Image of woman, with text.

EP. 8 Emphasizing the Importance of Food Safety During Cancer Care

Newsletter

Stay up to date on cancer updates, research and education

Related Content

$Bleximenib and Venclexta treatment were well tolerated in a phase 1b trial for relapsed or refractory acute myeloid leukemia with mostly low-grade side effects.$

Bleximenib/Venclexta Treatment Combo is Safe in Early AML Trial

ByDr. Jenny O’Nions

December 16th 2025

Emmy-winning journalist and author Suleika Jaouad recently delivered the keynote address at the inaugural Blood Cancer Heroes celebration.

Suleika Jaouad, Reporting From the Front Lines of Leukemia

BySuleika Jaouad

December 12th 2025

story about ponatinib and blinatumomab for ALL

A New Option Without Traditional Chemotherapy for Ph+ ALL

ByAriana Pelosci

December 7th 2025

AML

Azacitidine Plus Venclexta Superior to Chemo in Acute AML

ByJonah Feldman

December 7th 2025

acute myeloid leukemia

Black Patients With AML Face Lower Survival Outcomes

December 7th 2025

Trending on CURE

FDA Approves Enhertu Plus Perjeta in Advanced HER2+ Breast Cancer

SHARON Trial Offers a Potential Approach for Advanced Pancreatic Cancer

FDA Grants Fast Track Status to Muzastotug for Some Colorectal Cancers

FDA Grants Breakthrough Designation to INCA-33989 in Essential Thrombocythemia

Cancer in the Rearview Mirror

© 2025 MJH Life Sciences^®

All rights reserved.